Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514523 · ClinicalTrials.gov registry record · NA
QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events
A NA study of Diabetes and Diabetes Mellitus, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 3
- Study locations
NCT04514523: Completed NA study of Diabetes and Diabetes Mellitus, sponsored by Yale University.
NCT04514523 is a NA study of Diabetes and Diabetes Mellitus that has completed, run by Yale University. The registered enrollment target is 91 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04514523, a NA study of Diabetes and Diabetes Mellitus, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to co-develop a toolkit (known as the QBSAfe toolkit) with patients, family caregivers, and clinicians that focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety for patients with diabetes mellitus.
Primary Outcome
Patient responses to post-visit questionnaires.
Conditions Studied
Interventions
- OTHER QBSAfe Toolkit
Study Locations (3)
Connecticut
- Yale University - New Haven
- Trinity Health of New England - Waterbury
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2020-09-22 |
| Phase | NA |
What the finished NCT04514523 record still lists
NCT04514523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which QBSAfe Toolkit is the first listed.
NCT04514523 reports a single indexed study location in Connecticut, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04514523 about?
NCT04514523 is a clinical study titled "QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events". The purpose of this study is to co-develop a toolkit (known as the QBSAfe toolkit) with patients, family caregivers, and clinicians that focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety for patients with diabetes mellit...
What is the current status of trial NCT04514523?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2020-04-28. Estimated completion is 2020-09-22.
What conditions does trial NCT04514523 study?
This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus.
What interventions are being tested in trial NCT04514523?
The interventions under investigation include: QBSAfe Toolkit (OTHER).
Who is sponsoring clinical trial NCT04514523?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04514523 being conducted?
This trial has 3 study locations across Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04514523's enrollment target sits among peer trials
91 202nd of 338 higher than 137 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI